FDA Approves IsoPSA Test, a New Tool for Detecting High-Grade Prostate Cancer

The Targeted Science Editorial Team | December 2025

The U.S. Food and Drug Administration has approved IsoPSA, a next generation blood test designed to help physicians identify men at higher risk for developing aggressive prostate cancer. The decision marks a significant advance in prostate cancer diagnostics and could reshape how clinicians determine when a biopsy is warranted.

Developed by Cleveland Diagnostics, IsoPSA examines structural variations in the prostate specific antigen (PSA) protein rather than measuring its concentration alone. Traditional PSA testing has long been criticized for limited specificity; levels can rise for reasons unrelated to cancer, such as benign prostatic enlargement or inflammation. These false alarms have contributed to decades of overdiagnosis and unnecessary biopsies.

IsoPSA aims to change that dynamic. By analyzing PSA isoforms linked more closely with malignant activity, the test has demonstrated an improved ability to distinguish between benign conditions and high-grade prostate cancer, the form most associated with long-term health consequences.

Regulators cleared the assay for use in men age 50 and older with elevated PSA levels, positioning IsoPSA as an adjunct tool in determining the need for biopsy. Clinicians expect the test to reduce rates of avoidable procedures, streamline referrals, and better target high-risk patients for further evaluation.

The approval also provides formal backing to a test that had already gained traction in clinical practice. IsoPSA has been included in the National Comprehensive Cancer Network’s “Prostate Cancer Early Detection” guidelines since 2022, reflecting growing confidence among urologists and oncologists in its predictive value.

Industry analysts say the decision could accelerate adoption of advanced biomarker testing across urology practices, adding competitive pressure to long-standing diagnostic approaches. Hospitals and private practices continue to invest in tools that improve risk stratification and reduce unnecessary interventions, particularly as health systems face increasing scrutiny over cost, outcomes, and patient experience.

For patients, the FDA approval adds another option to a crowded and often confusing screening landscape. Prostate cancer remains one of the most commonly diagnosed cancers among American men, and decisions around screening and biopsy have historically involved complex tradeoffs. Supporters of IsoPSA argue that the test provides clearer signals at a pivotal decision point, before a man agrees to an invasive tissue biopsy.

As adoption grows, researchers are expected to continue evaluating the test’s performance across diverse populations and clinical settings. For now, urologists anticipate that IsoPSA will become an important component of modern prostate cancer risk assessment, offering a more precise alternative to the traditional PSA test.

For a detailed analysis of IsoPSA testing, including supporting peer-reviewed studies, read the full report by our editorial team here: IsoPSA: Advancing High Grade Prostate Cancer Detection

Medical Disclaimer: This article and report are for informational purposes only and are not intended as medical advice. Readers should consult a licensed healthcare professional for diagnosis, treatment, or recommendations regarding prostate health or any medical condition.